Clinical Trials Browser

Phase 2 × Withdrawn × E-3810 × Clear all

NCT02747797 2018-08-02

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms